MODULE 1: Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) — Dr Flinn

• Long-term follow-up from studies documenting the efficacy and safety of ibrutinib- and acalabrutinib-based regimens for patients with treatment-naïve CLL
• Available results from the Phase III SEQUOIA trial comparing zanubrutinib to bendamustine/rituximab (BR) as first-line therapy for previously untreated CLL
• Phase III data sets (eg, ELEVATE-RR, ALPINE studies) documenting the comparative efficacy and tolerability of first- and second-generation Bruton tyrosine kinase (BTK) inhibitors in patients with previously treated CLL; implications for up-front decision-making
• Outcomes observed with venetoclax-based up-front regimens in older/unfit and fit patients with treatment-naïve CLL
• Major efficacy and safety findings from the Phase III GLOW trial evaluating ibrutinib in combination with venetoclax as first-line treatment for CLL

MODULE 2: Relapsed/Refractory (R/R) CLL; Novel Investigational Strategies — Dr Smith

• Key factors in the selection and sequencing of therapy for patients who experience relapse on first-line BTK or Bcl-2 inhibition
• Long-term efficacy and safety results with BTK inhibitors and venetoclax-based therapy in patients with R/R CLL; clinical utility of rechallenging with agents used in a prior line of treatment
• Current role of PI3K inhibitors in the CLL treatment paradigm
• Mechanism of action of pirtobrutinib; published clinical trial results, potential clinical role and ongoing and planned studies of pirtobrutinib for CLL
• Other promising agents and strategies under investigation for CLL

MODULE 3: Follicular Lymphoma (FL) — Dr Leonard

• Appropriate integration of obinutuzumab into current FL treatment algorithms; practical implications of the Phase IV GAZELLE study demonstrating the efficacy and safety of a shorter (90-minute) infusion of obinutuzumab
• Long-term clinical trial findings with lenalidomide/rituximab for patients with treatment-naïve and R/R FL; current role in clinical practice
• Current clinical utility of PI3K inhibitors in R/R FL; implications of the withdrawal of the indications for idelalisib, umbralisib and duvelisib
• Incidence of EZH2 mutations in patients with FL; key findings with and optimal use of tazemetostat for previously treated FL with and without EZH2 mutations
• Mechanism of action of and available safety and efficacy data with investigational bispecific antibodies (eg, mosunetuzumab, glofitamab, epcoritamab) for R/R FL; FDA breakthrough therapy designation for mosunetuzumab and potential clinical role
• Early results with and ongoing investigation of other novel agents and strategies for FL

MODULE 4: Mantle Cell Lymphoma (MCL) — Dr Lunning

• Research database supporting the use of ibrutinib, acalabrutinib or zanubrutinib for R/R MCL; key factors in patient selection for these agents
• Primary results from the Phase III SHINE study of ibrutinib in combination with BR as first-line treatment for older patients with MCL
• Available data with other BTK inhibitors alone or in combination with other systemic therapies for patients with previously untreated MCL
• Early-phase research experience with venetoclax alone or combined with other agents for MCL; current nonresearch role and practical implementation of venetoclax therapy
• Efficacy and safety findings observed in the Phase I/II BRUIN study of pirtobrutinib in patients with R/R MCL; potential clinical role
• Ongoing investigation of other novel agents and strategies for MCL

MODULE 5: Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Sehn

• Improvement in progression-free survival reported from the Phase III POLARIX study comparing polatuzumab vedotin with chemotherapy to R-CHOP for previously untreated DLBCL; implications for clinical practice
• Early data with and ongoing and planned evaluation of other novel agents (eg, tafasitamab, selinexor, BTK inhibitors) in the first-line setting
• Available efficacy and safety findings with polatuzumab vedotin in combination with BR for patients with R/R DLBCL; optimal incorporation into current management algorithms
• Key data leading to the FDA approval of tafasitamab/lenalidomide for R/R DLBCL; patient selection for treatment with this regimen
• Optimal sequencing and practical implementation of selinexor for R/R DLBCL
• Principal findings contributing to the recent FDA approval of loncastuximab tesirine for R/R DLBCL; current role in clinical practice
• Available data with and ongoing and planned evaluation of CD20 x CD3 bispecific antibodies in DLBCL

MODULE 6: Chimeric Antigen Receptor (CAR) T-Cell Therapy — Dr Hill

• Longer-term follow-up from clinical trials evaluating the efficacy and safety of axicabtagene ciloleucel (axi-cel), tisagenlecleucel and lisocabtagene maraleucel (liso-cel) for R/R DLBCL
• Available results from Phase III studies (eg, ZUMA-7, TRANSFORM, BELINDA) of CAR T-cell therapy as second-line treatment for DLBCL; recent FDA approval of axi-cel in this setting
• Key efficacy and safety data with approved (brexucabtagene autoleucel) and investigational (liso-cel) CAR T-cell platforms for MCL
• Principal outcomes from pivotal studies (eg, ZUMA-5, ELARA) evaluating CAR T-cell therapy for FL; FDA approval of axi-cel and current role in clinical practice
• Available findings from the liso-cel monotherapy cohort and the liso-cel/ibrutinib cohort of the Phase I/II TRANSCEND CLL 004 trial for R/R CLL
• Ongoing studies evaluating CAR T-cell therapy in various lymphoma subtypes; appropriate patient referral

Thank you for your interest in our CME program taking place in Chicago, IL. At this time ONLINE "IN-PERSON" PREREGISTERATION is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED - ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 6:30 PM Central Time on Sunday June 5. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (702 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2022 ASCO Annual Meeting website.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Please note, onsite registration does not guarantee meal service which will be based on availability.